SK pharmteco Expands Stability Storage Capacity In California To Support Small Molecule Drug Substance And Drug Product Programs

Rancho Cordova, CA — SK pharmteco, a global contract development and manufacturing organization (CDMO), announces the expansion of its stability storage capacity at its El Dorado Hills, California facility. This expansion complements the organization’s existing stability capabilities, meeting the growing demand for drug substance (DS) and drug product (DP) stability studies, and enhancing support for current and future client needs.

The new stability chambers offer a 40% increase in capacity and are fully validated. This expansion enables SK pharmteco to accommodate the increasing volume of stability studies.

“Our expanded stability storage capacity, combined with our team's extensive analytical development and validation experience for stability indicating methods, strengthens our ability to meet our clients’ evolving needs as their programs progress.” said Shankar Sankaran, Executive Director, Analytical, SK pharmteco. “Whether supporting standalone analytical projects or integrated manufacturing programs, this expansion enhances our ability to deliver flexible, efficient solutions at every stage of development – from clinical through commercial.”

All ICH storage conditions are supported, with qualified and mapped equipment and chamber monitoring that meet full CGMP requirements. With all chambers located at the same site as the analytical testing, clients benefit from streamlined workflows and faster turnaround times. Additional chambers are planned as part of a broader facility expansion in Q4 2025.

This expansion is the latest example of how SK pharmteco continues to invest in its capabilities to deliver reliable analytical testing solutions that empower the success of our clients.

Contact us today to learn how our team can help drive confidence and keep your stability programs moving forward.